Eli Lilly and Company has become a key player in the manufacturing of tirzepatide, a groundbreaking treatment for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, showcases significant capacity to improve glycemic control and reduce the risk of cardiovascular disease. The complex manufacturing process of tirzepatide requires a s